GlassScriptPhysician profile
Brandy N Holthaus
NPI 1972922953
$1,305.51
in general payments reported to CMS, 2019-2025
19 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $164 · 2023: $262 · 2024: $298 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.63 |
| Education | $115.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.83 | 2023-2025 | |
| Exact Sciences Corporation | $138.35 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $115.62 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $95.71 | 2021 | |
| Pfizer INC. | $86.53 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.15 | 2025 | Shingrix, Pediarix, Bexsero |
| Novo Nordisk INC | $61.44 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $59.61 | 2021-2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2022-2024 | Airsupra, Farxiga |
| Dexcom, INC. | $43.07 | 2021-2022 | |
| Theratechnologies INC. | $42.92 | 2025 | Egrifta, Trogarzo |
| Amgen INC. | $41.25 | 2024 | Otezla, Repatha |
| Abbott Laboratories | $40.42 | 2022-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.66 | 2021 | |
| Hologic Sales and Service, LLC | $32.28 | 2024 | Third Wave, Thinprep 2000 Processor, Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $28.29 | 2022 | |
| Boston Scientific Corporation | $27.30 | 2022 | |
| Viiv Healthcare Company | $13.75 | 2023 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Holthaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.